Related Experiment Video
Updated: Jul 4, 2025

08:53
Recurrent Escherichia coli Urinary Tract Infection Triggered by Gardnerella vaginalis Bladder Exposure in Mice
Published on: December 4, 2020
6.1K
A New Strategy to Prevent "Deja vUTI".
Tyler D Bold1,2
1Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
NEJM Evidence
|February 6, 2024
Summary
Recurrent urinary tract infections (UTIs) affect up to 30% of women annually. Understanding the causes of these recurring UTI symptoms is crucial for developing effective, evidence-based treatments.
Area of Science:
- Urology
- Infectious Diseases
- Women's Health
Background:
- Urinary tract infections (UTIs) are common, with up to 30% of women experiencing recurrence within a year.
- A subset of women (1%) suffer from frequent recurrent UTIs (six or more episodes annually).
- Recurrent UTIs, termed "deja vUTI," present a significant clinical challenge.
Discussion:
- The precise pathophysiological mechanisms underlying recurrent UTIs remain incompletely understood.
- Current clinical management of recurrent UTIs often relies on empirical practices rather than robust evidence.
- There is a need for cohesive pathophysiological understanding to guide treatment strategies.
Key Insights:
- Deja vu describes a feeling of recurrence, mirroring the experience of recurrent UTIs.
- High rates of UTI recurrence highlight a significant unmet medical need.
- The lack of clear mechanisms hinders the development of targeted therapies.
Outlook:
- Future research should focus on elucidating the pathophysiology of recurrent UTIs.
- Developing evidence-based treatment guidelines is essential for improving patient outcomes.
- Advancing the understanding of recurrent UTIs can lead to novel therapeutic interventions.
Related Concept Videos
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Hand hygiene
3.2K
Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Hand washing...
3.2K

